Allogeneic Transplantation in T-Cell Lymphomas

Seminars in Hematology

Volumn 51, Issue 1, 2014, Pages 67-72

  Schmitz, Norbert ^a   Wu, Huei Shan ^a   Glass, Bertram ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CUTANEOUS T CELL LYMPHOMA; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; EVENT FREE SURVIVAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATOSPLENIC T CELL LYMPHOMA; HLA MATCHING; HUMAN; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MYCOSIS FUNGOIDES; MYELOABLATIVE CONDITIONING; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SEZARY SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84892855294     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.11.010     Document Type: Article

References (31)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lympnoid tissues. Lyon, France: IARC; 2008.
2. Schmitz N., Trümper L., Ziepert M., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
3. Mak V., Hamm J., Chhanabhai M., et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survival. J Clin Oncol 2013, 31:1970-1976.
4. Dreger P. Role of allotransplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Ann Oncol 2011, 22. iv36-9.
5. Jantunen E., Wiklund T., Juvonen E., et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004, 33:405-410.
6. Song K.W., Mollee P., Keating A., et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978-985.
7. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172-2176.
8. Dodero A., Spina F., Narni F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2011, 26:520-526.
9. Smith S.M., Burns L.J., van Besien K., et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013, 31:3100-3109.
10. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008, 26:2264-2271.
11. Kyriakou C., Canals C., Finke J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009, 27:3951-3958.
12. Glass B., Hasenkamp J., Jung W., et al. Allogeneic stem cell transplantation for patients with relapsed or chemorefractory T-cell lymphoma: role of high intensity conditioning. Ann Oncol 2011, 22. iv95.
13. Glass B., Hasenkamp J., Wulf G., et al. High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: results of a prospective study of the German High-Grade Non-Hodgkin Lymphoma Study Group. J Clin Oncol 2012, 30 suppl:8004.
14. Jacobsen E.D., Kim H.T., Ho V.T., et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sèzary syndrome. Ann Oncol 2011, 22:1608-1613.
15. Delioukina M., Zain J., Palmer J.M., et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012, 47:65-72.
16. Czajczynska A., Günther A., Repp R., et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell NHL. Biol Bone Marrow Transplant 2013, 19:1632-1637.
17. Corradini P., Vitolo U., Rambaldi A., et al. Intensified chemo-immunotherapy including up-front autologous or allogeneic stem cell transplantation (SCT) for young patients with newly diagnosed peripheral T-cell lymphomas: final results of a phase II multicenter prospective clinical trial. Blood 2012, 120:1984a.
18. Molina A., Zain J., Arber D.A., et al. Durable clinical, cytogenetic and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sèzary syndrome and mycosis fungoides. J Clin Oncol 2005, 23:6163-6171.
19. Duarte R.F., Canals C., Onida F., et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010, 28:4492-4499.
20. Duarte R.F., Boumendil A., Onida F., et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sèzary syndrome: the experience of the EBMT Lymphoma Working Party with an extended five-year follow up. Blood 2013, 122:2094a.
21. Jaccard A., Gachard N., Marin B., et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMet Dex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117:1834-1839.
22. Kim S.J., Kim K., Kim B.S., et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009, 27:6027-6032.
23. Murashige N., Kami M., Kishi Y., et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005, 130:561-567.
24. Fukashima T., Miyazaki Y., Honda S., et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005, 19:824-834.
25. Hishizawa M., Kanda J., Utsunomiya A., et al. Transplantaion of allogeneic hematopoietic stem cell for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
26. Mansour M.R., Dogan A., Morris E.C., et al. Allogeneic transplantation for hepatosplenic αß T-cell lymphoma. Bone Marrow Transplant 2005, 35:931-934.
27. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
28. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30:631-636.
29. d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem cell transplantation in peripjeral T-cell lymphoma: NKG-T-01. J Clin Oncol 2012, 30:3093-3099.
30. Reimer P., Rüdiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
31. Chen R., Palmer J.M., Thomas S.H., et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.